Literature DB >> 1858678

Effects of immunosuppressive therapy in biopsy-proved myocarditis and borderline myocarditis on left ventricular function.

S R Jones1, A Herskowitz, G M Hutchins, K L Baughman.   

Abstract

Twenty patients with decreased left ventricular (LV) function and endomyocardial biopsy-proved myocarditis (9 patients) or borderline myocarditis (11 patients) were studied to determine whether these 2 histologic subsets of patients with inflammatory heart disease differed in their response to a 6- to 8-week course of immunosuppressive therapy. All patients received a regimen of prednisone, 1.0 mg/kg/day, and azathioprine, 1.5 mg/kg/day, followed by repeat endomyocardial biopsy and reevaluation of LV function. LV function improved significantly in the group with borderline myocarditis, as assessed by LV stroke work--end-diastolic volume ratio (0.26 +/- 0.17 to 0.54 +/- 0.31 kg.m.ml-1, p less than 0.02), heart rate corrected velocity of circumferential shortening (0.49 +/- 0.30 to 0.80 +/- 0.29 circ.s-1, p less than 0.05), and LV ejection fraction (0.30 +/- 0.15 to 0.47 +/- 0.13, p less than 0.05). LV end-diastolic and end-systolic volume indexes also decreased significantly from 129 +/- 40 to 94 +/- 38 (p less than 0.05) and 90 +/- 37 to 49 +/- 26 ml (p less than 0.02), respectively. No significant change in these indexes of LV function or volume occurred in the myocarditis group. Whereas salutory improvements in cardiac output and filling pressures were found in both groups, objective improvement in LV function assessed by complementary indexes of contractility was greatest in the borderline myocarditis group. It is concluded that short-term immunosuppressive therapy improves LV contractile function and appears to be associated with regression of ventricular dilatation in patients with borderline myocarditis to a greater extent than patients with myocarditis.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1858678     DOI: 10.1016/0002-9149(91)90834-8

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  12 in total

Review 1.  Influence of myocarditis on left ventricular function.

Authors:  K L Baughman
Journal:  Trans Am Clin Climatol Assoc       Date:  2000

Review 2.  [Therapy of dilated cardiomyopathies with and without inflammation].

Authors:  G Hufnagel; S Pankuweit; B Maisch
Journal:  Med Klin (Munich)       Date:  1998-04-15

3.  Clinical outcomes of acute myocarditis in childhood.

Authors:  K J Lee; B W McCrindle; D J Bohn; G J Wilson; G P Taylor; R M Freedom; J F Smallhorn; L N Benson
Journal:  Heart       Date:  1999-08       Impact factor: 5.994

Review 4.  Diagnosis and management of pediatric myocarditis.

Authors:  Desmond Bohn; Lee Benson
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 5.  [State of diagnostics and therapy of inflammatory cardiomyopathie].

Authors:  H P Schultheiss; U Kühl
Journal:  Internist (Berl)       Date:  2008-01       Impact factor: 0.743

6.  Immunosuppressive treatment for myocarditis and borderline myocarditis in children with ventricular ectopic rhythm.

Authors:  S Balaji; H B Wiles; M A Sens; P C Gillette
Journal:  Br Heart J       Date:  1994-10

Review 7.  Acute and Fulminant Myocarditis: a Pragmatic Clinical Approach to Diagnosis and Treatment.

Authors:  Enrico Ammirati; Giacomo Veronese; Manlio Cipriani; Francesco Moroni; Andrea Garascia; Michela Brambatti; Eric D Adler; Maria Frigerio
Journal:  Curr Cardiol Rep       Date:  2018-09-26       Impact factor: 2.931

8.  Interleukin-1 beta modulates the growth and phenotype of neonatal rat cardiac myocytes.

Authors:  C M Thaik; A Calderone; N Takahashi; W S Colucci
Journal:  J Clin Invest       Date:  1995-08       Impact factor: 14.808

Review 9.  Myocarditis.

Authors:  Lori A Blauwet; Leslie T Cooper
Journal:  Prog Cardiovasc Dis       Date:  2010 Jan-Feb       Impact factor: 8.194

10.  Peripartum Cardiomyopathy.

Authors:  Kenneth L. Baughman
Journal:  Curr Treat Options Cardiovasc Med       Date:  2001-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.